10.6084/m9.figshare.8172743.v1
Mark Stein
Mark
Stein
Jyoti Malhotra
Jyoti
Malhotra
Rohinton Tarapore
Rohinton
Tarapore
Usha Malhotra
Usha
Malhotra
Ann Silk
Ann
Silk
Nancy Chan
Nancy
Chan
Lorna Rodriguez
Lorna
Rodriguez
Joseph Aisner
Joseph
Aisner
Robert Aiken
Robert
Aiken
Tina Mayer
Tina
Mayer
Bruce Haffty
Bruce
Haffty
Jenna Newman
Jenna
Newman
Salvatore Aspromonte
Salvatore
Aspromonte
Praveen Bommareddy
Praveen
Bommareddy
Ricardo Estupinian
Ricardo
Estupinian
Charles Chesson
Charles
Chesson
Evita Sadimin
Evita
Sadimin
Shengguo Li
Shengguo
Li
Daniel Medina
Daniel
Medina
Tracie Saunders
Tracie
Saunders
Melissa Frankel
Melissa
Frankel
Aparna Kareddula
Aparna
Kareddula
Sherrie Damare
Sherrie
Damare
Elayne Wesolowsky
Elayne
Wesolowsky
Christian Gabel
Christian
Gabel
Wafik El-Deiry
Wafik
El-Deiry
Varun Prabhu
Varun
Prabhu
Joshua Allen
Joshua
Allen
Martin Stogniew
Martin
Stogniew
Wolfgang Oster
Wolfgang
Oster
Joseph Bertino
Joseph
Bertino
Steven Libutti
Steven
Libutti
Janice Mehnert
Janice
Mehnert
Andrew Zloza
Andrew
Zloza
Additional file 1: of Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration
Springer Nature
2019
ONC201
Cancer
Solid tumors
Immunotherapy
Immuno-oncology
Dopamine
2019-05-22 05:00:00
Journal contribution
https://springernature.figshare.com/articles/journal_contribution/Additional_file_1_of_Safety_and_enhanced_immunostimulatory_activity_of_the_DRD2_antagonist_ONC201_in_advanced_solid_tumor_patients_with_weekly_oral_administration/8172743
Figure S1. Ratio of cleaved:total cytokeratin 18 (M30/M65 ELISA assay) in patients treated with weekly ONC201. Figure S2. Maximum fold change over baseline of immune cytokines and effector molecules in all ONC201-treated patients in the two dosing cohorts (every three weeks and weekly dosing schedules). Figure S3. (A) Maximum fold change of serum prolactin levels in the serum relative to baseline when compared to maximum concentration of ONC201 in the serum of the patients treated on a weekly schedule. Figure S4. Maximum fold induction of caspase-cleaved cytokeratin 18 levels in the serum relative to baseline when compared to maximum concentration of ONC201 in the serum of the patients treated on a weekly schedule. Figure S5. Timing of maximum fold-induction of immune cytokines and effects. Figure S6. Serum PSA (ng/mL) of ONC201-treated prostate cancer patients. Table S1. Treatment-related adverse events (AEs) in patients treated with ONC201 on a weekly schedule. Table S2. Pharmacokinetic parameters for 625âmg of ONC201 after the first dose of cycle 1 and after the first dose of cycle 2 (nâ=â17). (DOCX 324 kb)